Occlude Defect ,
To provide global doctors and patients with safe and innovate medical devices to treat cardiovascular diseases
Being an innovative company, we consistently explore new idea and methods
Guangzhou, China – On October 23rd, the first global press release of the Lifetech Absnow™ biodegradable Atrial Septal Defect closure system was held at the Guangdong Cardiovascular Institute, Guangdong General Hospital, gathering representatives from multiple media around China.
Lifetech Scientific attended the TCT 2018 conference and released the feasibility study data of the Lifetech IBS™ sirolimus-eluting iron absorbable coronary stent system.
From September 15th to September 19th, Lifetech Respiration, a subsidiary company of Lifetech Scientific debuted its latest innovation, the Cinenses® lung volume reduction reverser system at the ERS International Congress 2018 in Paris, France.
On April 25, 2018, Lifetech was included in the ranking of the "the Most Attentive List Company by Institution Investors of Shenzhen-Hongkong Stock Connect "
On April 19, 2018, Lifetech (1302.HK) was awarded as "listed company with the Best Medical Devies and Diagnosis "
LifeTech Scientific (Shenzhen) Co., Ltd. as the winner of the first prize of the Guangdong Science and Technology Award for 2017
Lifetech is a leading developer, manufacturer and vendor of advanced minimally invasive medical devices for cardiovascular and peripheral vascular diseases and disorders.
Founded in 1999, we are now the second largest provider of congenital heart defect occluders in the world and the largest provider to BRIC countries.